STOCKHOLM, August 26, 2020 -
A summary of the resolutions taken by the Meeting follows. For complete details concerning all resolutions, please see the Meeting documents that are available on the Company's website, www.elekta.com.
Accounting documents and discharge from liability
Dividend and disposition of the Company's earnings
The Meeting resolved to allocate this year's earnings, meaning a dividend to the shareholders corresponding to
Board of Directors and committees
The Meeting resolved that the number of Directors shall be seven with no deputies.
The Meeting resolved that the remuneration to the Board of Directors shall be unchanged in relation to the previous year, which means that the Chairman of the Board of Directors shall receive
Auditor
he registered auditing firm
Guidelines for salary and other remuneration to executive management
he Meeting approved the Board of Directors' proposal regarding guidelines for salary and other remuneration to executive management.
Performance Share Plan 2020
The Meeting resolved on the establishment of the Performance Share Plan 2020, and on the transfer of own shares due to the Performance Share Program 2020.
The program includes the President and CEO, executive management and nominated key contributors, all in all about 30 employees, who will qualify for allotment, free of charge, of shares of series B in Elekta following expiry of the three-year performance period and provided a continued employment in the Group until the end of the Performance Year 2022/2023. The maximum number of shares that can be allotted is dependent on the degree of fulfilment of one performance target, Elekta's Total Shareholder Return ("TSR") relative to the OMXS30 Index over a three-year period. For the Performance Share Plan 2020, the minimum performance requirement is that Elekta TSR outperform the OMXS30 Index with at least +0.1 per cent. The maximum performance level requires that Elekta TSR outperform the OMXS30 Index at or above +15 per cent. The performance target shall be adjusted at the occurrence of events affecting the number of outstanding shares in the Company, or unforeseen material events affecting the
Assuming maximum allotment under the Performance Share Plan 2020 and a share price of
Acquisition and transfer of own shares
The Meeting authorized the Board of Directors, during the period until the next Annual General Meeting to decide, on one or more occasions, on the acquisition of a total number of own shares of series B so that, after the purchase, the Company holds not more than ten percent of the total number of shares in the Company. Furthermore, the Meeting authorized the Board of Directors, during the period until the next Annual General Meeting to decide, on one or more occasions, on the transfer of own shares of series B in conjunction with the financing of company acquisitions and other types of strategic investments and acquisitions, and not exceeding the maximum number of treasury shares held by the Company at any given time.
In view of the Performance Share Plan 2020, the Meeting resolved that not more than 1,000,000 shares of series B can be transferred with deviation from the shareholders' preferential rights, and to authorize the Board of Directors, during the period until the next Annual General Meeting to decide, on one or more occasions, on the transfer of not more than 485,830 own shares of series B on Nasdaq Stockholm to cover certain expenditures, mainly social security contributions.
Instructions for the Nomination Committee
The Meeting resolved on an instruction for the appointment of the Nomination Committee.
Amendment of the Articles of Association
The Meeting resolved to amend item 8 in the Articles of Association by removing information regarding record date as an adaptation to an upcoming legislative change. Moreover, the Meeting resolved to insert a new item regarding collection of powers of attorneys and postal voting, and on a few non-material amendments attributable to formalities.
# # #
For further information, please contact:
Tel: +46 76 611 76 25, e-mail: cecilia.ketels@elekta.com
Time zone: CET: Central European Time
The information was submitted for publication at
About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to - and benefits from - more precise, personalized radiotherapy treatments. Headquartered in
https://news.cision.com/elekta/r/report-from-the-annual-general-meeting-2020-in-elekta,c3181660
https://mb.cision.com/Main/35/3181660/1297685.pdf
(c) 2020 Cision. All rights reserved., source